DHHS → node
The MaineCare team is working to develop a MaineCare logo that will be used to strengthen our identity when we engage with stakeholders and assist in outreach in our communities.
We want your help! Please take a couple of minutes to complete this survey: https://www.surveymonkey.com/r/SHXNW2F
Joined by Acting Child and Family Services Director Bobbi Johnson
Health and Human Services Commissioner Jeanne Lambrew appeared before the Government Oversight Committee today to provide testimony on the child welfare system. She was joined by Bobbi Johnson, Acting Director of the Office of Child and Family Services.
The remarks of Commissioner Lambrew and Acting Director Johnson, as prepared for delivery, are below.
Commissioner Lambrew:
The proposed rule change would remove the asset test, Section 2.1, effective retroactive to January 1, 2024. The proposed rule change is based on a legislative change to 22 M.R.S. § 254-D(4)(B) made by P.L. 2023, ch. 412, Part EEEEE. This rule change is consistent with a recent MaineCare Eligibility Manual proposed rule change which would remove the asset test for all Medicare Savings Plan coverage types. Retroactive rulemaking is permissible under 22 M.R.S.
Maine exercises an option for Broad Based Categorical Eligibility under 7 C.F.R. § 273.2(j)(2) which includes a 200% Federal Poverty Level (FPL) test.
The Division of Policy posts all proposed and recently adopted rules on MaineCare’s Policy and Rules webpage. This website keeps the proposed rules
The EVV requirements for Home Health providers delivering services under Section 40 were implemented on January 1, 2023.
We continue to offer weekly provider and aggregator trainings. All trainings are online via Microsoft Teams.
NOTE: The Absorb training system has been updated to allow providers to register for trainings more than once.
EVV Training Schedule
In a letter released October 27, 2023, the U.S. Department of Health and Human Services (HHS) announced the plan to transition two COVID-19 oral therapeutics from government supplied to the commercial market. The transition process started on November 1, 2023, for Paxlovid manufactured by Pfizer and Lagevrio, manufactured by Merck.
In order to ensure MaineCare members get the health care services they need, and have the information necessary to make informed decisions, MaineCare has created a new Gender Affirming Care Coverage Guide. This guide helps answer member’s questions about what MaineCare covers and offers helpful links to find providers who offer this care.